Investing in Biotech Stocks

Biotech companies play by different rules. Here is the framework for evaluating them.

Why biotech is different

Most public companies are valued on their current earnings and cash flow. You pay a price relative to what the business earns today. Biotech companies, especially pre-revenue ones, are valued almost entirely on what might happen in the future: whether a drug in clinical trials gets approved, whether a pipeline asset becomes a commercial product, whether the company survives long enough to find out. Standard metrics like P/E and FCF yield do not apply to a company that has no revenue yet. Biotech investing requires a different vocabulary and a different set of questions.

The most important question: Cash Runway

For a pre-revenue biotech, cash runway is the single most important metric. A company with 6 months of runway is in survival mode. A company with 24 months of runway has time to execute on its pipeline without the pressure of an emergency capital raise. As a rule of thumb, less than 12 months of runway is a risk flag. Above 18 months gives the management team real operational flexibility. When a biotech reports earnings, the first thing most analysts check is the cash position and the updated runway estimate.

Clinical trial phases explained

Clinical development is the process of proving a drug is safe and effective. It happens in stages, and each stage is a gate.

Dilution risk

Biotech companies rarely generate revenue early in their life, so they fund operations by selling shares. Every time they do, existing shareholders own a smaller piece of the same company. A company that has doubled its share count over three years has effectively cut the value of each original share in half, assuming the business itself has not grown proportionally. Watch the total share count trend over time. Moderate dilution is normal and expected. Extreme dilution — 50% or more share count growth per year — signals a company burning cash faster than it can execute.

Gross margin for commercial-stage biotechs

Once a biotech has approved products and starts generating revenue, gross margin becomes relevant again. Pharmaceutical and biotech products typically have very high gross margins — 70% to 90% is normal — because the cost to manufacture is low relative to what it sells for. Gross margin below 60% for a commercial-stage biotech warrants investigation. It can indicate manufacturing challenges, pricing pressure, or a less differentiated product.

Revenue growth

For commercial-stage biotechs, revenue growth measures whether the approved product is gaining traction in the market. Early commercial launches are closely watched by analysts. Strong first-year revenue growth after a launch confirms that physicians are adopting the drug and that the commercial team is executing. Weak revenue growth after approval is a red flag even if the science is solid.

Pipeline breadth and risk

A company with a single drug in a single trial has binary risk: the trial succeeds or fails, and the stock goes up or down dramatically accordingly. A company with multiple drugs across multiple trials in different therapeutic areas has more diversified risk. One failure does not wipe out the whole investment thesis. When evaluating a biotech, count how many pipeline assets are in Phase 2 or later, and in how many different disease areas.

How Stock Pixie scores biotech

The Biotech Bargain Hunter screener applies a composite score weighted toward cash runway, dilution rate, gross margin for commercial-stage companies, and revenue growth. Because standard valuation metrics like P/E do not apply to most biotechs, the screener is designed to surface companies that are financially resilient — well-funded, not excessively dilutive — with commercial momentum if applicable. It is a starting point for investigation, not a substitute for reading the pipeline in detail.